NASDAQ:PCSA - Processa Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$10.52
▼ -1.52 (-12.62%)
1 month | 3 months | 12 months
Get New Processa Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PCSA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PCSA

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$0.00
▼ -100.00% Downside Potential
This price target is based on 2 analysts offering 12 month price targets for Processa Pharmaceuticals in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $10.52.
Buy
The current consensus among 2 contributing investment analysts is to buy stock in Processa Pharmaceuticals.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/11/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/10/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/9/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/7/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/5/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/4/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/2/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/4/2021

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/8/2020BenchmarkInitiated CoverageBuyHigh
i
10/28/2020Craig HallumInitiated CoverageBuyLow
i
(Data available from 3/4/2016 forward)
Processa Pharmaceuticals logo
Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops drugs for the unmet medical needs in the United States. Its lead product candidate is PCS499, an oral tablet that is in Phase II clinical trials for the treatment of necrobiosis lipoidica, a chronic disfiguring condition. The company is also developing PCS12852, a novel selective 5-hydroxytryptamine 4 (5-HT4) receptor agonist that is in Phase II clinical trials for the treatment of post-operative ileus; and PCS6422, an oral, potent, selective, and irreversible inhibitor that is in Phase I clinical trials for treating metastatic colorectal and breast cancer. It also has license agreement with Akashi Therapeutics, Inc. to develop and commercialize PCS100, an anti-fibrotic and anti-inflammatory drug. The company was founded in 2015 and is based in Hanover, Maryland.
Read More

Today's Range

Now: $10.52
$10.52
$11.83

50 Day Range

MA: $8.19
$5.96
$13.14

52 Week Range

Now: $10.52
$3.40
$13.35

Volume

1,213 shs

Average Volume

62,421 shs

Market Capitalization

$111.15 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Processa Pharmaceuticals?

The following Wall Street sell-side analysts have issued stock ratings on Processa Pharmaceuticals in the last year: Benchmark Co., and Craig Hallum.
View the latest analyst ratings for PCSA.

What is the current price target for Processa Pharmaceuticals?

0 Wall Street analysts have set twelve-month price targets for Processa Pharmaceuticals in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Processa Pharmaceuticals in the next year.
View the latest price targets for PCSA.

What is the current consensus analyst rating for Processa Pharmaceuticals?

Processa Pharmaceuticals currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe PCSA will outperform the market and that investors should add to their positions of Processa Pharmaceuticals.
View the latest ratings for PCSA.

What other companies compete with Processa Pharmaceuticals?

How do I contact Processa Pharmaceuticals' investor relations team?

Processa Pharmaceuticals' physical mailing address is 7380 COCA COLA DRIVE SUITE 106, HANOVER MD, 21076. The company's listed phone number is 443 776 3133 and its investor relations email address is [email protected] The official website for Processa Pharmaceuticals is www.processapharmaceuticals.com.